EXEL's shares surge 50% in a year on the back of the strong performance of its lead drug Cabometyx. We are optimistic about ...

XB-010 is under clinical development by Exelixis and currently in Phase I for Triple-Negative Breast Cancer (TNBC).

Russia and other hostile states have become increasingly brazen in adopting “gray zone” attacks against Europe and the United States, leaving defense officials with a dilemma: How to respond ...

Extreme Networks, Inc. , a leader in AI-powered automation for networking, today announced plans to release financial results for its second fiscal quarter 2025, ended December 31, 2024. The company ...

Logitech International (SIX: LOGN) today announced that it expects to release third quarter fiscal year 2025 financial results on Tuesday, January 28, 2025 at 1:00 p.m. Pacific Standard Time (PST) and ...

With new treatments in neurology, and more in development in cardiology and autoimmune diseases, precision medicine is moving beyond cancer and rare disease.